Glycosaminoglycan C3 protects against AF64A-induced cholinotoxicity in a dose-dependent and time-dependent manner

Brain Research

Volumn 1015, Issue 1-2, 2004, Pages 96-102

  Rose, M ^a   Dudas, B ^b   Cornelli, U ^a   Hanin, I ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

A (25 35); AF64A; Alzheimer's disease; Animal model; Degenerative disease: Alzheimer's miscellaneous; Disorders of the nervous system; Neurodegeneration

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; COMPLEMENT COMPONENT C3; ETHYLCHOLINE MUSTARD AZIRIDINIUM; GLYCOSAMINOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; AZIRIDINES; CELL DEATH; CHOLINE; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC FIBERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLYCOSAMINOGLYCANS; HEPARINOIDS; HIPPOCAMPUS; MALE; NEUROPROTECTIVE AGENTS; NEUROTOXINS; RATS; RATS, INBRED F344;

EID: 3042513692     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.04.048     Document Type: Article

References (48)

1. Bartus R.T. Physostigmine and recent memory: effects in young and aged nonhuman primates. Science. 206:1979;1087-1089
2. Bowen D.M., Smith C.B., White P., Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 99:1976;459-496
3. Castillo G.M., Ngo C., Cummings J., Wight T.N., Snow A.D. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J. Neurochem. 69:1997;2452-2465
4. Caughey B. Scrapie associated PrP accumulation and its prevention: insights from cell culture. Br. Med. Bull. 49:1993;860-872
5. Conti L., Re F., Lazzerini F., Morey L.C., Ban T.A., Santini V., Modafferi A., Postiglione A. Glycosaminoglycan polysulfate (Ateroid) in old-age dementias: effects upon depressive symptomatology in geriatric patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 13:1989;977-981
6. Conti L., Placidi G.F., Cassano G.B. Ateroid in the treatment of dementia: results of a clinical trial. Mod. Probl. Pharmacopsychiatry. 23:1989;76-84
7. Cornelli U. The therapeutic approach to Alzheimer's disease. Haremberg J., Casu B. Non-Anticoagulant Action of Glycosaminoglycans. 1996;249-279 Plenum, New York
8. Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;403
9. Dudas B., Cornelli U., Lee J.M., Hejna M.J., Walzer M., Lorens S.A., Mervis R.F., Fareed J., Hanin I. Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25-35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol. Aging. 23:2002;97-104
10. Emre M., Geula C., Ransil B.J., Mesulam M.M. The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected beta-amyloid in the rat brain. Neurobiol. Aging. 13:1992;553-559
11. Fisher A., Hanin I. Potential animal models for senile dementia of Alzheimer's type, with emphasis on AF64A-induced cholinotoxicity. Annu. Rev. Pharmacol. Toxicol. 26:1986;161-181
12. Fisher A., Mantione C.R., Abraham D.J., Hanin I. Long-term central cholinergic hypofunction induced in mice by ethylcholine aziridinium ion (AF64A) in vivo. J. Pharmacol. Exp. Ther. 222:1982;140-145
13. Fonnum F. Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities. Biochem. J. 115:1969;465-472
14. Frautschy S.A., Baird A., Cole G.M. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc. Natl. Acad. Sci. U. S. A. 88:1991;8362-8366
15. Giordano T., Pan J.B., Monteggia L.M., Holzman T.F., Snyder S.W., Krafft G., Ghanbari H., Kowall N.W. Similarities between beta amyloid peptides 1-40 and 40-1: effects on aggregation, toxicity in vitro, and injection in young and aged rats. Exp. Neurol. 125:1994;175-182
16. Giovannelli L., Casamenti F., Scali C., Bartolini L., Pepeu G. Differential effects of amyloid peptides beta-(1-40) and beta-(25-35) injections into the rat nucleus basalis. Neuroscience. 66:1995;781-792
17. Glenner G.G., Wong C.W., Quaranta V., Eanes E.D. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl. Pathol. 2:1984;357-369
18. Gupta-Bansal R., Frederickson R.C., Brunden K.R. Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. J. Biol. Chem. 270:1995;18666-18671
19. Hanin I. AF64A-induced cholinergic hypofunction. Prog. Brain Res. 84:1990;289-299
20. Hanin I. The AF64A model of cholinergic hypofunction: an update. Life Sci. 58:1996;1955-1964
21. Howlett D.R., Jennings K.H., Lee D.C., Clark M.S., Brown F., Wetzel R., Wood S.J., Camilleri P., Roberts G.W. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration. 4:1995;23-32
22. Kisilevsky R., Lemieux L.J., Fraser P.E., Kong X., Hultin P.G., Szarek W.A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat. Med. 1:1995;143-148
23. Kondo J., Honda T., Mori H., Hamada Y., Miura R., Ogawara M., Ihara Y. The carboxyl third of tau is tightly bound to paired helical filaments. Neuron. 1:1988;827-834
24. Kowall N.W., McKee A.C., Yankner B.A., Beal M.F. In vivo neurotoxicity of beta-amyloid [beta(1-40)] and the beta (25-35) fragment. Neurobiol. Aging. 13:1992;537-542
25. Ksiezak-Reding H., Liu W.K., Yen S.H. Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res. 597:1992;209-219
26. Leveugle B., Scanameo A., Ding W., Fillit H. Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport. 5:1994;1389-1392
27. Lorens S.A., Kindel G., Dong X.W., Lee J.M., Hanin I. Septal choline acetyltransferase immunoreactive neurons: dose-dependent effects of AF64A. Brain Res. Bull. 26:1991;965-971
28. Lorenzo A., Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. U. S. A. 91:1994;12243-12247
29. Ma Q., Dudas B., Daud A., Iqbal O., Hoppensteadt D., Jeske W., Cornelli U., Lee J., Lorens S., Mervis R., Hanin I., Capila I., Linhardt R., Fareed J. Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3. Thromb. Res. 105:2002;303-309
30. Ma Q., Dudas B., Hejna M., Cornelli U., Lee J.M., Lorens S., Mervis R., Hanin I., Fareed J. The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. Thromb. Res. 105:2002;447-453
31. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 82:1985;4245-4249
32. Mervis R.F., McKean J., Zats S., Gum A., Reinhard R., Dudas B., Cornelli U., Lee J.M., Lorens S.A., Fareed J., Hanin I. Neurotrophic effects of the glycosaminoglycan C3 on dendritic arborization and spines in the adult rat hippocampus: a quantitative Golgi study. CNS Drug Rev. 6:2000;44-46
33. Miller D.L., Papayannopoulos I.A., Styles J., Bobin S.A., Lin Y.Y., Biemann K., Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 301:1993;41-52
34. Passeri M., Cucinotta D. Ateroid in the clinical treatment of multi-infarct dementia. Mod. Probl. Pharmacopsychiatry. 23:1989;85-94
35. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, London
36. Podlisny M.B., Ostaszewski B.L., Squazzo S.L., Koo E.H., Rydell R.E., Teplow D.B., Selkoe D.J. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem. 270:1995;9564-9570
37. Pollack S.J., Sadler I.I., Hawtin S.R., Tailor V.J., Shearman M.S. Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells. Neurosci. Lett. 184:1995;113-116
38. Pollack S.J., Sadler I.I., Hawtin S.R., Tailor V.J., Shearman M.S. Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion. Neurosci. Lett. 197:1995;211-214
39. Rogers J., Schultz J., Brachova L., Lue L.F., Webster S., Bradt B., Cooper N.R., Moss D.E. Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease. Res. Immunol. 143:1992;624-630
40. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 89:1992;10016-10020
41. Roher A.E., Ball M.J., Bhave S.V., Wakade A.R. Beta-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem. Biophys. Res. Commun. 174:1991;572-579
42. Rose M., Dudas B., Cornelli U., Hanin I. Protective effect of glycosaminoglycan C3 on AF64A-induced cholinergic lesions in rats. Neurobiol. Aging. 24:2003;481-490
43. Santini V. A general practice trial of Ateroid 200 in 8, 776 patients with chronic senile cerebral insufficiency. Mod. Probl. Pharmacopsychiatry. 23:1989;95-100
44. Shaffer L.M., Dority M.D., Gupta-Bansal R., Frederickson R.C., Younkin S.G., Brunden K.R. Amyloid beta protein (A beta) removal by neuroglial cells in culture. Neurobiol. Aging. 16:1995;737-745
45. Sigurdsson E.M., Lorens S.A., Hejna M.J., Dong X.W., Lee J.M. Local and distant histopathological effects of unilateral amyloid-beta 25-35 injections into the amygdala of young F344 rats. Neurobiol. Aging. 17:1996;893-901
46. Snow A.D., Sekiguchi R.T., Nochlin D., Kalaria R.N., Kimata K. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am. J. Pathol. 144:1994;337-347
47. Snow A.D., Kinsella M.G., Parks E., Sekiguchi R.T., Miller J.D., Kimata K., Wight T.N. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. Arch. Biochem. Biophys. 320:1995;84-95
48. Wischik C.M., Novak M., Thogersen H.C., Edwards P.C., Runswick M.J., Jakes R., Walker J.E., Milstein C., Roth M., Klug A. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 85:1988;4506-4510